Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control

Table 1

GLP-1-based drugs.

GLP-1-based drugs	Generic name	Disease	References
GLP-1 receptor agonists	Exenatide (synthetic form of exendin-4)	Diabetes	[43, 46, 47]
		Vascular disease	[61, 65, 70]
		Nonalcoholic steatohepatitis	[61, 93, 96]
		Nephropathy	[99, 101, 105, 107]
		Neurodegenerative brain disorder	[87, 92]
	Liraglutide	Diabetes	[48]
		Vascular disease	[8, 23, 58–60]
		Neurodegenerative brain disorder	[24, 84, 89]
		Nonalcoholic steatohepatitis	[9, 28, 95]
		Nephropathy	[14]
		Asthma	[30, 108]
		Psoriasis	[31, 111, 112]
	Lixisenatide	Neurodegenerative brain disorder	[90]
	Albiglutide
	Taspoglutide
	Dulaglutide
	DPP-4 inhibitors	Sitagliptin	Diabetes	[7, 19, 45]
			Vascular disease	[26, 64, 65, 72]
			Neurodegenerative brain disorder	[91]
Nephropathy			[25, 107]
Des-fluoro-sitagliptin		Vascular disease	[66]
Alogliptin		Vascular disease	[67]
		Nephropathy	[105, 106]
Linagliptin		Nephropathy	[104]
		Vascular disease	[63]
Vildagliptin (PKF-275-055)		Diabetes	[49]
		Nephropathy	[103]
NVP-DPP728		Diabetes	[44]
Anagliptin		Nephropathy	[105]
Saxagliptin		Nephropathy	[102]